Abstract
Uveal melanoma (UM) is the most common primary intraocular malignancy and the second most common form of melanoma. UM has a strong tendency for metastatic disease, and no effective treatments have yet been identified. Activating oncogenic mutations are commonly found in GNAQ and GNA11 in UM, and inhibiting key downstream effectors of the GNAQ/11 signaling pathway represents a rational therapeutic approach for treating metastatic UM. Chen et al., doi:10.1038/onc.2013.418, now confirm activation of the MAPK and PKC pathways as a result of GNAQ and GNA11 activating mutations in melanocytes, and they demonstrate that MAPK activation occurs downstream of PKC activation. PKC inhibitors disrupt MAPK signaling and block proliferation of GNAQ/11 mutant UM cell lines and slow the in vivo growth of xenografted UM tumors without inducing their shrinkage. However, a combination of PKC and MEK inhibition led to sustained MAPK pathway inhibition and tumor regression in vivo. Hence, the authors concluded that MEK and PKC inhibition is synergistic, with superior efficacy to treatment of GNAQ/GNA11 mutant UMs with either drug alone.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Identification of novel chemotherapeutic strategies for metastatic uveal melanoma
Scientific Reports Open Access 17 March 2017
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Harbour JW . Genomic, prognostic, and cell-signaling advances in uveal melanoma. Am Soc Clin Oncol Educ Book 2013; 2013: 388–391.
Zuidervaart W, van Nieuwpoort F, Stark M, Dijkman R, Packer L, Borgstein AM et al. Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS. Br J Cancer 2005; 92: 2032–2038.
Onken MD, Worley LA, Long MD, Duan S, Council ML, Bowcock AM et al. Oncogenic mutations in GNAQ occur early in uveal melanoma. Invest Ophthalmol Vis Sci 2008; 49: 5230–5234.
Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T et al. Mutations in GNA11 in uveal melanoma. N Engl J Med 2010; 363: 2191–2199.
Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O'Brien JM et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009; 457: 599–602.
Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA et al. Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 2010; 330: 1410–1413.
Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM . Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 2013; 45: 133–135.
Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N et al. Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 2013; 45: 933–936.
Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS et al. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 2012; 18: 408–416.
Chen X, Wu Q, Tan L, Porter D, Jager MJ, Emery C et al. Combined PKC and MEK inhibition in uveal melanoma with GNAQ and GNA11 mutations. Oncogene (e-pub ahead of print 21 October 2013; doi:10.1038/onc.2013.418).
Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS . The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 2012; 7: e29622.
Khalili JS, Yu X, Wang J, Hayes BC, Davies MA, Lizee G et al. Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res 2012; 18: 4345–4355.
Ho AL, Musi E, Ambrosini G, Nair JS, Deraje Vasudeva S, de Stanchina E et al. Impact of combined mTOR and MEK inhibition in uveal melanoma is driven by tumor genotype. PLoS One 2012; 7: e40439.
Acknowledgements
This work was supported by in part by the National Institutes of Health (NIH 5R01 CA12597007 (JWH), NIH 1R01 CA16187001 (JWH and AMB)), the Melanoma Research Alliance (JWH), Melanoma Research Foundation (JWH).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Sagoo, M., Harbour, J., Stebbing, J. et al. Combined PKC and MEK inhibition for treating metastatic uveal melanoma. Oncogene 33, 4722–4723 (2014). https://doi.org/10.1038/onc.2013.555
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2013.555
This article is cited by
-
Targeting GNAQ/11 through PKC inhibition in uveal melanoma
Cancer Gene Therapy (2022)
-
Palmitoylation of GNAQ/11 is critical for tumor cell proliferation and survival in GNAQ/11-mutant uveal melanoma
Frontiers of Medicine (2022)
-
Blue light-triggered optogenetic system for treating uveal melanoma
Oncogene (2020)
-
An insight into the molecular genetics of a uveal melanoma patient cohort
Journal of Cancer Research and Clinical Oncology (2018)
-
Identification of novel chemotherapeutic strategies for metastatic uveal melanoma
Scientific Reports (2017)